Disease diagnostics biomarker database

Search Cancer Biomarker Database

This feature is available only to customers who have subscribed to premium membership. If you have subscribed to our premium membership please login to access this feature. If you wish to signup for Sciclips/subscribe to our premium membership, please click here. You will need a Sciclips account to subscribe.

Services offered

SciClips Consultancy

Fostering innovation through scientific intelligence

Sciclips consultancy service team is comprised of highly qualified and experienced scientists who have several years of research experience in academic and industrial laboratories. We offer following custom services at competitive price:

Scientific and technical areas covered: Drug discovery, Stem cells, Genomics, Proteomics, Biomarkers, Clinical diagnostics, Companion diagnostics, Molecular diagnostics, Personalized medicine (theranostics), Plant and agricultural biotechnology

Patent search

: Custom intellectual property (IP) analysis; Comprehensive patent database search and evaluation

Custom data analysis and data mining

: From patents, research articles, meeting abstracts and web based information. Custom meta analysis.

Competitive intelligence analysis

: Comprehensive analysis of competitive technologies and products; Technology trend prediction; Identification of technology licensing opportunities; Acquisition target identification; Identification of collaborative technology development opportunities.

Technology development

: Identification of potential development opportunities in drug discovery assay development, cell based assay development, recombinant protein expression (in vitro and in vivo) and mass spectrometry/proteomics reagents and tools; Product development strategy.

Diagnostics and Theranostics technology development

: Diagnostic assay development; Diagnostic target identification (molecular or protein or miRNA or metabolomic biomarkers); Prognostic and drug efficacy biomarkers; Theranostics tools, biomarkers and therapeutic drug targets; Identification of emerging technologies and methods.

Custom database development

Customized bioinformatics tools

: Offered through our partners.

Proteomics and Drug discovery services (laboratory based)

: Offered through our partners.

For more information on our consultancy services please contact us at contact@sciclips.com or email us using the contact form

Receive news updates by email

Biomarker Pathway

Biomarkers for predicting the efficacy of endocrine therapy consisting of tamoxifen, anastrozole, letrozole or exemestane in breast cancer patients

Biomarkers for predciting the efficacy of anthracycline-based adjuvant chemotherapy with epirubicin in breast cancer patients

Biomarkers for predicting the efficacy of anthracyline treatment in breast cancer patients

Biomarkers for predicting the efficacy of treatment response to pazopanib (Votrient) in renal cell carcinoma patients

Biomarkers associated overall survival in metastatic pancreatic cancer patients treated with ganitumab (GAN; AMG 479) in combination with gemcitabine

Biomarkers associated resistance to cetuximab in metastatic colorectal cancer patients

Biomarkers associated with irinotecan-associated toxicity and drug response in colorectal cancer patients

Biomarkers associated with taxane resistance in breast cancer patients

Biomarkers to predict the efficacy of high-dose methotrexate (MTX) treatment in childhood acute lymphoblastic leukaemia (ALL) patients

Biomarkers for accessing the efficacy of carboplatin, abraxane, and bevacizumab combination therapy in patients with non-small cell lung cancer (NSCLC)

Biomarkers for assessing cardiac effects of doxorubicin (DOX) in children treated for acute lymphoblastic leukemia (ALL)

Biomarkers for determining the therapeutic efficacy of ABL tyrosine kinase inhibitor (imatinib) in chronic myeloid leukemia (CML) patients-1

Biomarkers for determining whether a patient with breast cancer is likely to respond to treatment with trastuzumab, lapatinib or pertuzumab

Biomarkers for identifying or predicting the predisposition to hepatotoxicity or the risk of developing hepatotoxicity and/or elevated ALT or AST in a subject treated with COX-2 selective inhibitor, lumiracoxib

Biomarkers for predciting the efficacy of adjuvant tamoxifen treatment in estrogen receptor (ER)-positive, operable breast cancer patients

Predictive biomarkers for determining whether a patient will benefit from taxane treatment for breast cancer

Biomarkers for prediciting the response to etoposide, gemcitabine, Erlotinib and Cetuximab treatments in non-small cell lung cancer patients

Biomarkers for prediciting the efficacy of bevacizumab treatment in breast cancer patients

Biomarkers for prediciting the efficacy of bevacizumab treatment in colorectal cancer patients

Biomarkers for predicting doxorubicin cardiotoxicity in childhood acute lymphoblastic leukemia (ALL)

Biomarkers for predicting response of a cancer cell tissue to IGF-1R treatment (e.g. IGF1R inhibitor TKI)

Biomarkers for predicting response to endocrine therapy (ET) in ER-alpha positive Stage IV breast cancer

Biomarkers for predicting sunitinib induced cardiac toxicity in metastatic renal cell carcinoma patients

Biomarkers for predicting taxane-induced neuropathy in breast cancer patients

Biomarkers for predicting the benefit from gemcitabine-based chemotherapy after curative-intent surgery in pancreatic adenocarcinoma

Biomarkers for predicting the clinical outcome of anti EGFR therapy (cetuximab or panitumumab) in metastatic colorectal cancer patients

Biomarkers for predicting the clinical outcomes of treatment with motesanib in thyroid cancer patients

Biomarkers for predicting the clinical outcomes of treatment with motesanib in non-small cell lung cancer patients

Biomarkers for predicting the clinical outcomes of treatment with motesanib in breast cancer patients

Biomarkers for predicting the efficacy a combination therapy with bevacizumab (anti-VEGF) plus erlotinib (anti-EGFR) in hepatocellular carcinoma patients

Biomarkers for predicting the efficacy calcitriol treatment in lung cancer patients

Biomarkers for predicting the efficacy of ANA773 tosylate, an oral TLR7-selective agonist, in patients with advanced solid tumors

Biomarkers for predicting poorer survival outcome in head and neck cancer patients treated with gefitinib

Biomarkers for predicting the efficacy of cetuximab treatment in colorectal cancer patients

Biomarkers for predicting the efficacy of dasatinib and docetaxel combination treatment in patients with castration-resistant progressive prostate cancer (CRPC).

Predictive biomarker for risk of endocrine therapy failure in breast cancer patients

Biomarkers for predicting the efficacy of EGFR targeting anti-cancer drugs in non-small cell lung cancer patients

Biomarkers for predicting the efficacy of erlotinib treatment in combination with placebo or R1507, a monoclonal antibody to IGF-1R, for advanced-stage non-small cell lung cancer (NSCLC)

Biomarkers for predicting the efficacy of erlotinib treatment in patients with advanced pancreatic cancer (APC)

Biomarkers for predicting the efficacy of everolimus, an oral mTOR inhibitor, in patients with palliative transitional cell carcinoma (TCC)

Biomarkers for predicting the efficacy of gemcitabine + bevacizumab (GB) combination treatment in advanced or metastatic pancreatic cancer patients

Biomarkers for predicting the efficacy of octreotide LAR treatment in breast cancer patients

Biomarkers for predicting the efficacy of sunitinib treatment in patients with advanced neuroendocrine tumors

Biomarkers for predicting the efficacy of the treatment with a HDAC inhibitor, Vorinostat, in breast cancer patients

Biomarkers for predicting the efficacy of the treatment with a HDAC inhibitor, SAHA (Vorinostat and Zolinza), in cutaneous T-cell lymphoma (CTCL) patients

Biomarkers for the early detection of cardiotoxicity from trastuzumab following anthracycline-based chemotherapy in breast cancer patients

Biomarkers for predicting the efficacy of trastuzumab treatment in metastatic breast cancer patients

Biomarkers for predicting the efficacy of pemetrexed treatment in non-small cell lung cancer patients

Biomarkers for predicting the efficacy of pemetrexed treatment in non-small cell lung cancer patients

Biomarkers for predicting the response to chemoradiotherapy (cisplatin, cetuximab, docetaxel, or erlotinib) in a patient suffering from a head and neck cancer

Biomarkers for predicting the survival in bevacizumab-treated advanced non-small cell lung cancer (NSCLC) patients

Biomarkers for predicting the efficacy of cytarabine/daunorubicin treatment in cytogenetically normal acute myeloid leukemia (CN-AML)

Biomarkers for predicting imatinib resistance in chronic myelogenous leukemia (CML) patients

Biomarkers for predicting the clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy.

Biomarkers for predicting the efficacy of capecitabine in rectal cancer patients

Predictive biomarkers of ipilimumab on melanoma patients' T-cells

Prognostic biomarkers in patients with metastatic melanoma receiving IL-2 based immunotherapy

Predictive marker of response to antiestrogen therapy in node-neagtive breast cancer

Biomarkers for predicting the efficacy of pemetrexed treatment in patients with nonsquamous non-small cell lung cancer (NSCLC)

Biomarkers for predicting the response to treatment with an epidermal growth factor receptor (EGFR) inhibitor, erlotinib (Tarceva TM), in non-small cell lung cancer (NSCLC) patients-1

Biomarkers for predicting the efficacy of bortezomib treatment in mantle cell lymphoma patients

Biomarkers for predicting the response to treatment with an epidermal growth factor receptor (EGFR) inhibitor, erlotinib (Tarceva TM), in non-small cell lung cancer (NSCLC) patients-2

Biomarkers for predicting the efficacy of taxane treatment in endometrial cancer patients

Biomarkers for predicting the efficacy of bevacizumab treatment in American Joint Committee on Cancer (AJCC) stage III melanoma patients

Biomarkers for predicting the efficacy of lenalidomide or Revimid RTM treatment in patients with non-Hodgkin's lymphoma

Biomarkers for determining the therapeutic efficacy of ABL tyrosine kinase inhibitor (imatinib) in chronic myeloid leukemia patients-2

Biomarkers for predicting overall survival in patients with advanced pancreatic cancer receiving gemcitabine (GEM) monotherapy

Biomarkers associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

Biomarkers for predicting the response of a non-small cell lung cancer patient to treatment with an epidermal growth factor receptor (EGFR) inhibitor, erlotinib (Tarceva TM)

Biomarkers for predicting the efficacy of lenalidomide and pomalidomide in myeloma patients

Biomarkers for predicting the efficacy of COX-2 inhibitor flurbiprofen, indomethacin and other non-steroidal anti-inflammatory drugs (NSAIDs) in cancer patients

Biomarkers for predicting the efficacy of COX-2 inhibitors flurbiprofen, indomethacin and other non-steroidal anti-inflammatory drugs (NSAIDs) in cancer patients

Biomarkers for predicting the efficacy of COX-2 inhibitor in breast cancer patients

Biomarkers for the predicting the efficacy of treatment using EGFR inhibitors geftinib, erlotinib and cetuxima in lung cancer patients

Biomarkers associated with doxorubicin resistance in breast cancer

Biomarkers associated with tamoxifen resistance in breast cancer

Biomarkers associated with TRAIL resistance in Mantle cell lymphoma

Biomarkers associated with the efficacy of treatment using DNA methyltransferase inhibitors (DNMTi), 5-aza-2'-deoxycytidine (5-aza-CdR) or Zebularine, in prostate cancer patients

Biomarkers for predicting the efficacy and safety of bortezomib treatment in multiple myeloma patients

Biomarkers to identify colorectal cancer patients with K-RAS wild-type tumors who are more likely to benefit from irinotecancetuximab treatment